<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epigenetic inactivation of RASSF1A, a putative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor with proapoptotic activity, is frequently observed in a number of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, including a variety of epithelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, but has not been described in <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We have analysed the expression and methylation status of RASSF1A in Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>)-derived cell lines, primary <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and serum samples from <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>RASSF1A transcription was detectable in only 2/6 HL cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>Methylation-specific PCR and <z:chebi fb="0" ids="17137">bisulfite</z:chebi> genomic sequencing revealed that the RASSF1A promoter was hypermethylated in <z:hpo ids='HP_0000001'>all</z:hpo> four RASSF1A-nonexpressing cell lines </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi> treatment resulted in demethylation of the promoter and RASSF1A expression in these lines </plain></SENT>
<SENT sid="5" pm="."><plain>Hypermethylation of RASSF1A was also detected in 34/52 (65%) primary <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and in 2/22 serum samples from these patients </plain></SENT>
<SENT sid="6" pm="."><plain>Microdissection of Hodgkin/Reed-Sternberg (HRS) cells from several of these cases confirmed that the RASSF1A hypermethylation we detected in the analysis of whole <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> originated from the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell population </plain></SENT>
<SENT sid="7" pm="."><plain>Although hypermethylation of RASSF1A was detected in 5/6 non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL)-derived cell lines, only rare primary NHL (1/10 of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 1/12 of post-transplant <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 1/12 diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 0/27 of nasal <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 0/8 follicular center cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 0/4 mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 0/4 anaplastic large cell (Ki-1+) <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 0/2 MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) showed hypermethylation of the promoter </plain></SENT>
<SENT sid="8" pm="."><plain>No methylation was detected in any of the 14 <z:mpath ids='MPATH_458'>normal</z:mpath> PBMC </plain></SENT>
<SENT sid="9" pm="."><plain>These results point to an important role for epigenetic silencing of RASSF1A in the pathogenesis of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Inactivation of RASSF1A could be one mechanism by which HRS cells escape the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> that should occur following nonproductive immunoglobulin gene rearrangements </plain></SENT>
</text></document>